Where Will Pfizer Be in 3 Years?

The next three years have just become a bigger question mark for Pfizer (NYSE: PFE) than they were before. There are two competing factors taking shape, one internal to the drugmaker; the other is external, even though it was expected to be a possible answer to Pfizer's internal problems.Here's what's happening for Pfizer right now, and why investors still might want to take the long view with this high-yield stock.In some ways, the pharmaceutical industry is pretty simple: You make a drug, and you sell a drug. But this isn't a simple manufacturing business, and there are a lot of subtleties that have to be taken into consideration. For example, finding a new drug to sell is a long, complex, competitive, and capital-intensive process. That's why drugmakers are given a period of time when they can exclusively sell a new drug. Revenue and profits for new drugs can be huge, but there's an end date to that revenue stream.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool